Recent progress in the treatment of lupus nephritis

References

• Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late mani-festations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299–308.
   PubMed Web of Science ®Google Scholar
• Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch Intern Med. 2000;160(20):3136–40.
   PubMedGoogle Scholar
• Costenbader KH, Desai A, Alarcon GS, Hiraki LT, Shaykevich T, Brookhart MA, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63(6):1681–8.
   PubMed Web of Science ®Google Scholar
• Hiraki LT, Lu B, Alexander SR, Shaykevich T, Alarcon GS, Solomon DH, et al. End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum. 2011; 63(7) : 1988–97.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednis-olone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340(8822):741–5.
   Google Scholar
• Gourley MF, Austin HA, 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A ran-domized, controlled trial. Ann Intern Med. 1996;125(7):549–57.
   Google Scholar
• Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135(4):248–57.
   PubMed Web of Science ®Google Scholar
• Austin HA, 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10): 614–9.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garri-doEdEde R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophospha-mide. Arthritis Rheum. 2002;46(8):2121–31.
   Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de RamonGarrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1): 61–4.
   Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de RamonGarrido E, Danieli MG, et al. Early response to immu-nosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50(12):3934–40.
   Google Scholar
• Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse pro-liferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156–62.
   PubMed Web of Science ®Google Scholar
• Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and mainte-nance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16(4):1076–84.
   Google Scholar
• Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophospha-mide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28.
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5): 1103–12.
   PubMed Web of Science ®Google Scholar
• Kamanamool N, McEvoy M, AttiaJ, Ingsathit A, Ngamjanyapom P, Thakkinstian A. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010; 89(4) : 227–35.
   PubMed Web of Science ®Google Scholar
• Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010;19(6):703–10.
   Google Scholar
• Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69–78.
   PubMed Web of Science ®Google Scholar
• Grootscholten C, Ligtenberg G, Hagen EC, vandenWallBake AW, de Glas-Vos JW, Bijl M, et al. Azathioprine/methyl-prednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006;70(4): 732–42.
   Google Scholar
• Grootscholten C, Bajema IM, Florquin S, Steenbergen RI, Peutz-Kootstra CJ, Goldschmeding R, et al. Treatment with cyclo-phosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methyl-prednisolone in patients with proliferative lupus nephritis. Arthritis Rheum. 2007;56(3):924–37.
   Google Scholar
• Arends S, Grootscholten C, Derksen RH, Berger SP, de Sevaux RG, Voskuyl AE, et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis. 2011.
   Google Scholar
• Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49(1):128–40.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, Brito-Zeron P, Cuadrado MJ, Sanna G, et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol. 2009;40(3):159–69.
   Web of Science ®Google Scholar
• Diaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martinez-Berriotxoa A, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2011;11: 357–64.
   Google Scholar
• Rea Furie. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract]. Arthritis Rheum. 2009;60[Suppl. 10]:a1149.
   Google Scholar
• Lee YH, Lee HS, Choi SJ, Dai Ji J, Song GG. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20(6):636–40.
   Google Scholar
• Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19(6):606–15.
   Google Scholar
• Chen W, Tang X, Liu Q, Fu P, Liu F, Liao Y, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclo-phosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235–44.
   PubMed Web of Science ®Google Scholar
• Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, et al. Myco-phenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transpl. 2012;27:1467–72.
   PubMed Web of Science ®Google Scholar
• Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59(6):2156–63.
   PubMed Web of Science ®Google Scholar
• Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V + IV lupus nephritis with multitarget ther-apy. J Am Soc Nephrol. 2008;19(10):2001–10.
   PubMed Web of Science ®Google Scholar
• Lanata CM, Mahmood T, Fine DM, Petri M. Combination ther-apy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus. 2010;19(8):935–40.
   PubMed Web of Science ®Google Scholar
• Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova E, et al. Treatment of lupus nephritis with cyclosporine-an outcome analysis. Kidney Blood Press Res. 2007;30(2):124–8.
   PubMed Web of Science ®Google Scholar
• Zavada J, Pesickova S, Rysava R, Olejarova M, Horak P, Hrncir Z, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010;19(11): 1281–9.
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B, Lenz 0, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350(10):971–80.
   Google Scholar
• Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083–9.
   PubMed Web of Science ®Google Scholar
• Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as mainte-nance therapy for lupus nephritis. N Engl J Med. 2011;365(20): 1886–95.
   PubMed Web of Science ®Google Scholar
• Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028–35.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Yim CW, Ng WL, Wong WS. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus. 2009;18(12): 1091–5.
   Google Scholar
• Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008;47(11): 1678–81.
   PubMed Web of Science ®Google Scholar
• Tse KC, Lam MF, Tang SC, Tang CS, Chan TM. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus. 2007;16(1):46–51.
   Google Scholar
• Kasitanon N, Petri M, Haas M, Magder LS, Fine DM. Myco-phenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Lupus. 2008;17(1):40–5.
   Google Scholar
• Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77(2):152–60.
   PubMed Web of Science ®Google Scholar
• Dussol B, Morange S, Burtey S, Indreies M, Cassuto E, Mourad G, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis. 2008;52(4):699–705.
   PubMed Web of Science ®Google Scholar
• Jonsdottir T, Sundelin B, Welin Henriksson E, van Vollenhoven RF, Gunnarsson I. Rituximab-treated membranous lupus nephri-tis: clinical outcome and effects on electron dense deposits. Ann Rheum Dis. 2011;70(6):1172–3.
   Google Scholar
• Fomoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46.
   Google Scholar
• Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase Anca D, Roth D, et al. Effect of belimumab treatment on renal out-comes: results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus [abstract]. Arthritis Rheum. 201 1 ;63 [ Suppl 10] :2472.
   Google Scholar
• Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001;166(5):2913–6.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase II13, randomized, double-blind, placebo-con-trolled trial. Arthritis Rheum. 2010;62(10):3077–87.
   PubMed Web of Science ®Google Scholar
• Furie R, Nicholls K, Cheng T-T, Houssiau F, Burgos-Vargas R, Chen S-L, et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, ran-domized, double-blind, placebo-controlled phase II/III study [abstract]. Arthritis Rheum. 2011;63[Suppl 10]:2469.
   Google Scholar
• Wofsy D, Shropshire Stephanie M, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative outcome measures support opposing interpretations of data from a multicenter, randomized, double-blind, placebo-controlled phase II/III study [abstract]. Arthritis Rheum. 2011;63[Suppl 10]:2474.
   Google Scholar
• Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum. 2007;56(5):1384–96.
   PubMed Web of Science ®Google Scholar
• Kahlenberg JM, Kaplan MJ. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res Ther. 2011;13(1):203.
   PubMed Web of Science ®Google Scholar
• Alarcon GS, Calvo-Alen J, McGwin G, Jr, Uribe AG, Toloza SM, Roseman JM, et al. Systemic lupus erythematosus in a multi-ethnic cohort: LUMINA XXXV. Predictive factors of high dis-ease activity over time. Ann Rheum Dis. 2006;65(9):1168–74.
   Google Scholar
• Duran-Barragan S, McGwin G Jr, Vila LM, Reveille JD, Alarcon GS. Angiotensin-converting enzyme inhibitors delay the occur-rence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythe-matosus-results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford). 2008;47(7):1093–6.
   Google Scholar
• Norby GE, Holme I, Fellstrom B, Jardine A, Cole E, Abedini S, et al. Effect of fluvastatin on cardiac outcomes in kidney trans-plant patients with systemic lupus erythematosus: a randomized placebo-controlled study. Arthritis Rheum. 2009;60(4):1060–4.
   PubMed Web of Science ®Google Scholar
• Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol. 2006;177(5):3028–34.
   PubMed Web of Science ®Google Scholar
• Shimazu H, Kinoshita K, Hino S, Yano T, Kishimoto K, Nagare Y, et al. Effect of combining ACE inhibitor and statin in lupus-prone mice. Clin Immunol. 2010;136(2):188–96.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7(12):718–29.
   Google Scholar
• Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7(2):80–5.
   Google Scholar
• Pons-Estel GJ, Alarcon GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830–9.
   Google Scholar
• Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydrox-ychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6): 366–70.
   Google Scholar
• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–8.
   PubMed Web of Science ®Google Scholar
• Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken). 2010; 62(6):873–80.
   Google Scholar
• Ayodele OE, Okpechi IG, Swanepoel CR. Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology (Carlton). 2010;15(4):482–90.
   Google Scholar
• Weng CH, Hsu CW, Yu CC, Yen TH, Yang CW, Hung CC. Peritoneal dialysis and hemodialysis in systemic lupus erythe-matosus patients: comparison of clinical outcomes. Kidney Blood Press Res. 2009;32(6):451–6.
   PubMed Web of Science ®Google Scholar
• Rietveld A, Berden JH. Renal replacement therapy in lupus nephritis. Nephrol Dial Transpl. 2008;23(10):3056–60.
   PubMed Web of Science ®Google Scholar
• Kang SH, Chung BH, Choi SR, Lee JY, Park HS, Sun 10, et al. Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis. Korean J Intern Med. 2011;26(1):60–7.
   Google Scholar